SCHEMBL7102763

SCHEMBL7102763

CC(CCCCCC(=O)O)CC(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.52
LMNA P02545 1/20 0.52
NFKB1 P19838 1/20 0.52
PMP22 Q01453 1/20 0.52
FFAR4 Q5NUL3 2/20 0.52
FFAR1 O14842 2/20 0.52
ALDH1A1 P00352 3/20 0.50
GSTK1 Q9Y2Q3 1/20 0.48
GPR84 Q9NQS5 7/20 0.48
PPARG P37231 6/20 0.48
PPARD Q03181 6/20 0.48
PPARA Q07869 6/20 0.48
HDAC11 Q96DB2 5/20 0.48
TLR2 O60603 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
FABP4 P15090 2/20 0.48
PTPN1 P18031 2/20 0.48
SLC22A6 Q4U2R8 1/20 0.48
SLC22A8 Q8TCC7 1/20 0.48
MEN1 O00255 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL495924 1.00 TSHR (0.52) TSHRLMNANFKB1PMP22FFAR4
SCHEMBL2928747 1.00 TSHR (0.52) TSHRLMNANFKB1PMP22FFAR4
SCHEMBL494914 1.00 TSHR (0.52) TSHRLMNANFKB1PMP22FFAR4
SCHEMBL495661 1.00 TSHR (0.52) TSHRLMNANFKB1PMP22FFAR4
SCHEMBL494465 1.00 TSHR (0.52) TSHRLMNANFKB1PMP22FFAR4
SCHEMBL494627 1.00 TSHR (0.52) TSHRLMNANFKB1PMP22FFAR4
SCHEMBL22612512 1.00 TSHR (0.52) TSHRLMNANFKB1PMP22FFAR4
SCHEMBL22612532 1.00 TSHR (0.52) TSHRLMNANFKB1PMP22FFAR4
SCHEMBL22612520 1.00 TSHR (0.52) TSHRLMNANFKB1PMP22FFAR4
SCHEMBL493872 1.00 TSHR (0.52) TSHRLMNANFKB1PMP22FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113970606-B Metabolic markers for diagnosing attention deficit hyperactivity disorder syndrome in urine of children 首都医科大学附属北京儿童医院 2022-06-14 CN claimed
CN-113970606-A Metabolic markers for diagnosing attention deficit hyperactivity disorder syndrome in urine of children 首都医科大学附属北京儿童医院 2022-01-25 CN claimed
CN-101840785-B Novel electrolyte FUJIAN YUNXING ELECTRONICS CO LTD 2012-08-22 CN claimed
CN-101840785-A Novel electrolyte FUJIAN YUNXING ELECTRONICS CO LTD 2010-09-22 CN claimed
US-20260013535-A1 STEVIOL GLYCOSIDE SOLUBILITY ENHANCERS CARGILL, INCORPORATED (US) 2026-01-15 US disclosed
EP-4184225-B1 OPTICAL FILM MITSUBISHI GAS CHEMICAL CO (JP) 2025-12-03 EP disclosed
US-12458049-B2 Steviol glycoside solubility enhancers CARGILL, INCORPORATED (US) 2025-11-04 US disclosed
US-11717549-B2 Steviol glycoside solubility enhancers CARGILL, INCORPORATED (US) 2023-08-08 US disclosed
US-20230236340-A1 OPTICAL FILM MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2023-07-27 US disclosed
EP-4184225-A1 OPTICAL FILM MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2023-05-24 EP disclosed
CN-115803661-A Optical film 三菱瓦斯化学株式会社 2023-03-14 CN disclosed
US-20220339259-A1 ORALLY DELIVERED THERAPEUTICAL COMPOSITION AND USE THEREOF SHEN HAIFA (US) 2022-10-27 US disclosed
EP-0832913-A1 RANDOM SILOXANE COPOLYMER, PROCESS FOR PRODUCTION THEREOF, AND RESIN COMPOSITION CONTAINING THE COPOLYMER KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1998-04-01 EP disclosed
EP-0509458-B1 Multilayer structural material MITSUBISHI CHEM CORP (JP) 1996-07-17 EP disclosed
US-5328767-A Polyester with amide groups layer and aromatic polyester or olefin polymer layer for films, sheets and packaging material MITSUBISHI KASEI CORPORATION (JP) 1994-07-12 US disclosed
EP-0509458-A1 Multilayer structural material Mitsubishi Chemical Corporation (JP) 1992-10-21 EP disclosed
US-5102979-A POLYESTER AND PROCESS FOR PRODUCING THE SAME MITSUBISHI KASEI CORPORATION (JP) 1992-04-07 US disclosed
EP-0404116-A2 Polyester and process for producing the same MITSUBISHI KASEI CORPORATION (JP) 1990-12-27 EP disclosed
US-4782132-A Process for producing a copolyester MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) 1988-11-01 US disclosed
US-3996292-A Process for the preparation of aliphatic dialdehydes RHONE-POULENC S.A. (FR) 1976-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12458049-B2 Steviol glycoside solubility enhancers SI, TAS2R7, TAS2R31 TSHR 4189/4885LMNA 4020/4885NFKB1 3810/4885
US-20260013535-A1 STEVIOL GLYCOSIDE SOLUBILITY ENHANCERS TAS2R7, TAS2R31, TAS2R40 TSHR 2374/4885LMNA 4221/4885NFKB1 4493/4885
US-11717549-B2 Steviol glycoside solubility enhancers SI, TAS2R7, TAS2R31 TSHR 4189/4885LMNA 4020/4885NFKB1 3810/4885
US-20220339259-A1 ORALLY DELIVERED THERAPEUTICAL COMPOSITION AND USE THEREOF FABP2, SLC27A1, SLC27A2 TSHR 4550/4885LMNA 2441/4885NFKB1 2951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.